IDEXX Laboratories (IDXX) Competitors

Stryker (NYSE:SYK) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.

Which has better valuation and earnings, SYK or IDXX?

Stryker has higher revenue and earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$22.60B	6.04	$2.99B	$7.76	46.05
IDEXX Laboratories	$3.90B	8.87	$887.87M	$10.67	39.98

Which has more volatility & risk, SYK or IDXX?

Stryker has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Do institutionals and insiders believe in SYK or IDXX?

77.1% of Stryker shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 5.2% of Stryker shares are held by insiders. Comparatively, 1.0% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media refer more to SYK or IDXX?

In the previous week, IDEXX Laboratories had 1 more articles in the media than Stryker. MarketBeat recorded 33 mentions for IDEXX Laboratories and 32 mentions for Stryker. IDEXX Laboratories' average media sentiment score of 1.40 beat Stryker's score of 1.38 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	30 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	26 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer SYK or IDXX?

Stryker presently has a consensus price target of $423.53, indicating a potential upside of 18.53%. IDEXX Laboratories has a consensus price target of $523.75, indicating a potential upside of 22.76%. Given IDEXX Laboratories' higher possible upside, analysts clearly believe IDEXX Laboratories is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.79
IDEXX Laboratories	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

Is SYK or IDXX more profitable?

IDEXX Laboratories has a net margin of 22.78% compared to Stryker's net margin of 13.25%. IDEXX Laboratories' return on equity of 55.82% beat Stryker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	13.25%	23.58%	11.37%
IDEXX Laboratories	22.78%	55.82%	26.48%

Does the MarketBeat Community prefer SYK or IDXX?

Stryker received 397 more outperform votes than IDEXX Laboratories when rated by MarketBeat users. However, 71.73% of users gave IDEXX Laboratories an outperform vote while only 64.53% of users gave Stryker an outperform vote.

Company	Underperform	Outperform
Stryker	Outperform Votes 935 64.53%	Underperform Votes 514 35.47%
IDEXX Laboratories	Outperform Votes 538 71.73%	Underperform Votes 212 28.27%

Summary

IDEXX Laboratories beats Stryker on 12 of the 19 factors compared between the two stocks.